Evidence Snapshot

Serine/threonine-protein kinase AKT

CHEMBL2111353 PROTEIN FAMILY Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T10:05:27Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 13, 2026, 7:05 PM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2111353

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase AKT as ChEMBL target CHEMBL2111353, mapped to UniProt P31751. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Serine/threonine-protein kinase AKT

PROTEIN FAMILY · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL2111353

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P31751

RAC-beta serine/threonine-protein kinase

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Serine/threonine-protein kinase AKT matters

As of 2026-09-13

Serine/threonine-protein kinase AKT is reviewed as RAC-beta serine/threonine-protein kinase (UniProt P31751); Serine/threonine-protein kinase AKT shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.; 9 linked drugs keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 192 compounds, and 161 assays, with lead potency reaching pChEMBL 9.7.

Protein context

RAC-beta serine/threonine-protein kinase

RAC-beta serine/threonine-protein kinase Sequence length is 481 aa.

Review this target as Serine/threonine-protein kinase AKT, mapped to UniProt P31751. ChEMBL maps the protein component as RAC-beta serine/threonine-protein kinase. Sequence length is 481 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P31751 Protein

Disease context

neoplasm

Serine/threonine-protein kinase AKT shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 9 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AFURESERTIB, CAPIVASERTIB, IPATASERTIB.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include AFURESERTIB, CAPIVASERTIB, IPATASERTIB, MIRANSERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 9 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 1 approved drug, 192 compounds, and 161 assays for this target. The dominant activity type is IC50. CHEMBL4795065 is the current potency anchor at pChEMBL 9.7.

Use CHEMBL4795065 as the tractability anchor when discussing potency (pChEMBL 9.7).

Activity source · ChEMBL 36 via Core Engine

1 approved pChEMBL 9.7

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Serine/threonine-protein kinase AKT matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P31751, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why neoplasm is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

192

Total Compounds

161

Total Assays

Approved Drugs

IC50: 156.0, KI: 5.0, EC50: 6.0, KD: 8.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL4795065	9.7	IC50	—
No preferred name CHEMBL5426352	9.5	IC50	—
No preferred name CHEMBL5414256	9.1	IC50	—
No preferred name CHEMBL3919089	9.0	IC50	—
No preferred name CHEMBL5402470	9.0	IC50	—